Skip to contentL
Lifecore Biomedical, Inc.
L
LFCRLifecore Biomedical, Inc. Q3 2023 · 10-Q
Revenue$26.54M$26.54M−24.7% vs Q3 2022 Net Income-$36.51M-$36.51MN/M vs Q3 2022 EPS Diluted-$1.20-$1.20N/M vs Q3 2022 Gross Profit$8,548,000−26.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lifecore Biomedical, Inc. · CIK 1005286 · Engraved from SEC EDGAR
Operating Cash Flowderived-$11,725,000N/M Free Cash Flowderived-$18,825,000N/M Margins · derivedGross margin32.2%−0.8 pt vs Q3 2022
Operating margin-24.6%+2.7 pt vs Q3 2022
Net margin-137.6%−99.0 pt vs Q3 2022
ended Feb 26, 2023 · filed Jun 2, 2023 · 96 d after period end